CP 640186 is a potent and selective inhibitor of Checkpoint kinase 1 (Chk1), primarily used in research and development within the pharmaceutical industry, particularly in oncology. It targets the DNA damage response pathway, making it valuable for studying cell cycle checkpoints, DNA repair mechanisms, and apoptosis. Its applications focus on investigating potential therapeutic interventions for cancer, including sensitizing tumor cells to DNA-damaging agents like chemotherapy and radiation. Researchers utilize this compound in preclinical studies to assess its efficacy and safety profile, aiming to develop novel anticancer drug candidates. Additionally, it is employed in biochemical assays to elucidate molecular interactions and signaling pathways, advancing drug discovery in personalized oncology medicine.